The USPSTF recommends screening for colorectal cancer using fecal occult blood testing, sigmoidoscopy, or colonoscopy in adults, beginning at age 50 years and continuing until age 75. The risks and benefits of these screening methods vary. Grade: A recommendation. Intervals for recommended screening strategies:
PROGRAM ATTRIBUTES
• Annual screening with high-sensitivity fecal occult blood testing • Sigmoidoscopy every 5 years, with high-sensitivity fecal occult blood testing every 3 years
• Screening colonoscopy every 10 years
Balance of Harms and Benefits
The benefits of screening outweigh the potential harms for 50-to 75-yearolds.
The likelihood that detection and early intervention will yield a mortality benefit declines after age 75 because of the long average time between adenoma development and cancer diagnosis.
Implementation
Focus on strategies that maximize the number of individuals who get screened. Practice shared decision-making; discussions with patients should incorporate information on test quality and availability. Individuals with a personal history of cancer or adenomatous polyps are followed by a surveillance regimen, and screening guidelines are not applicable.
Relevant USPSTF Recommendations
The USPSTF recommends against the use of aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer. This recommendation is available at www.uspreventiveservicestaskforce.org.
*These recommendations do not apply to individuals with specific inherited syndromes (Lynch Syndrome or Familial Adenomatous Polyposis) or those with inflammatory bowel disease.
For a summary of the evidence systematically reviewed in making these recommendations, the full recommendation statement, and supporting documents, go to www.uspreventiveservicestaskforce.org.
Disclaimer: Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the AHRQ or the U.S. DHHS.
Cost
Cost depends on the procedure and location. 
